The Ebola virus disease (EVD), formerly known as a hemorrhagic fever and 
discovered in 1976, is dangerous, highly infectious disease with very high 
mortality. There are no licensed therapeutics against EVD, although a range of 
medicines and therapies are currently being evaluated. During the 2014 Ebola 
outbreak, an experimental drug named ZMapp was administered on an emergency 
basis to seven patients of which five were recovered. Currently, since February 
2015, ZMapp is tested in clinical trials. ZMapp is a mixture (named a cocktail) 
of three chimaeric monoclonal antibodies (mAbs) of IgG class, which bind to 
three different epitopes on Ebola surface glycoprotein (GP). ZMapp was created 
by systematic selection of antibodies from two other three-component 
cocktails--MB-003 and ZMab the components of which were produced by rapid 
transient expression method in tobacco species of Australian origin--Nicotiana 
benthamiana. The ZMapp antibodies of pharmaceutical grade are manufactured in 
green-house grown N.benthamiana according to the cGMP (current Good 
Manufacturing Practice), using RAMP platform (Rapid Antibody Manufacturing 
Platform) and MagnICON system, which utilizes transient expression by 
magnifection method using viral vectors delivered to plant tissue by a 
bacterium--Agrobacterium tumefaciens. The applied glycosylation mutant of 
N.benthamiana (delta XTFT) synthesizes human-like, biantennary N-glycans, with 
terminal N-acetylglucoseamine and without typical of plants, immunogenic sugar 
epitopes-beta1,2-linked xylose and alpha1,3-linked fucose. Due to an absence of 
fucose on N-glycans attached to the Fc domains, the plant-produced anti-Ebola 
mAbs elicited significantly stronger antibody-dependent cellular cytotoxicity 
(ADCC) than the analogous anti-Ebola mAbs with fucosylated (alpha1,6-linked 
fucose) N-glycans produced in a mammalian CHO cell line--the basic expression 
system for the industrial production of recombinant therapeutical glycoproteins. 
As far as a vaccine against Ebola virus disease is considered, so-called Ebola 
Immunogenic Complex (EIC) consisting of assembled molecules of a humanized IgG 
mAb--6D8 specific for Ebola GPI with GP1 fused to the C-terminus of the heavy 
chains, was obtained by transient expression in N. benthamiana.